These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 3139571)

  • 1. Randomized clinical trial of testosterone replacement therapy in hypogonadal men.
    Conway AJ; Boylan LM; Howe C; Ross G; Handelsman DJ
    Int J Androl; 1988 Aug; 11(4):247-64. PubMed ID: 3139571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.
    Jockenhövel F; Vogel E; Kreutzer M; Reinhardt W; Lederbogen S; Reinwein D
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):61-71. PubMed ID: 8796140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of testosterone pellets in man.
    Handelsman DJ; Conway AJ; Boylan LM
    J Clin Endocrinol Metab; 1990 Jul; 71(1):216-22. PubMed ID: 2115044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial.
    Moutos D; Smith S; Zacur H
    Contraception; 1995 Aug; 52(2):105-9. PubMed ID: 8536446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of the endocrine manifestations of hepatic cirrhosis.
    Baker HW; Burger HG; de Kretser DM; Dulmanis A; Hudson B; O'Connor S; Paulsen CA; Purcell N; Rennie GC; Seah CS; Taft HP; Wang C
    Q J Med; 1976 Jan; 45(177):145-78. PubMed ID: 769039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LH and non-SHBG testosterone and estradiol levels during testosterone replacement of hypogonadal men: further evidence that steroid negative feedback increases as men grow older.
    Winters SJ; Wang C;
    J Androl; 2010; 31(3):281-7. PubMed ID: 19959827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label, phase 2, single centre, randomized, crossover design bioequivalence study of AndroForte 5 testosterone cream and Testogel 1% testosterone gel in hypogonadal men: study LP101.
    Wittert GA; Harrison RW; Buckley MJ; Wlodarczyk J
    Andrology; 2016 Jan; 4(1):41-5. PubMed ID: 26754331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM; Gow SM; Wu FC
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: further evidence that ageing enhances testosterone negative feedback. The Testoderm Study Group.
    Winters SJ; Atkinson L
    Clin Endocrinol (Oxf); 1997 Sep; 47(3):317-22. PubMed ID: 9373453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of long-term testosterone treatment on endocrine parameters in hypogonadal men: 12-year data from a prospective controlled registry study.
    Yassin A; Saad F; Alwani M; Aboumarzouk OM; Al-Zoubi RM; Nettleship J; Kelly D; Al-Ansari A
    Aging Male; 2022 Dec; 25(1):185-191. PubMed ID: 35903984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study.
    Skakkebaek NE; Bancroft J; Davidson DW; Warner P
    Clin Endocrinol (Oxf); 1981 Jan; 14(1):49-61. PubMed ID: 7014044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ethinyloestradiol on plasma levels of pituitary gonadotrophins, testicular steroids and sex hormone binding globulin in normal men.
    Van Look PF; Frölich M
    Clin Endocrinol (Oxf); 1981 Mar; 14(3):237-43. PubMed ID: 6790203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
    Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E
    J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coadministration of anastrozole sustains therapeutic testosterone levels in hypogonadal men undergoing testosterone pellet insertion.
    Mechlin CW; Frankel J; McCullough A
    J Sex Med; 2014 Jan; 11(1):254-61. PubMed ID: 24119010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of gonadotrophin secretion by steroid hormones in castrated male transsexuals. I. Effects of oestradiol infusion on plasma levels of follicle-stimulating hormone and luteinizing hormone.
    Goh HH; Chew PC; Karim SM; Ratnam SS
    Clin Endocrinol (Oxf); 1980 Feb; 12(2):165-75. PubMed ID: 6772356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
    Nieschlag E; Büchter D; Von Eckardstein S; Abshagen K; Simoni M; Behre HM
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):757-63. PubMed ID: 10619981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men.
    Amory JK; Anawalt BD; Blaskovich PD; Gilchriest J; Nuwayser ES; Matsumoto AM
    J Androl; 2002; 23(1):84-91. PubMed ID: 11780927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.